Vir Biotechnology (VIR) Share-based Compensation (2018 - 2026)

Vir Biotechnology has reported Share-based Compensation for 9 years, with the latest figure at $12.1 million in Q1 2026.

• Quarterly Share-based Compensation fell 14.03% year-over-year to $12.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (down 92.21% YoY) and the FY2025 annual result came in at $7.3 million, down 90.66% from the prior year.
• Share-based Compensation grew to $12.1 million in Q1 2026 per VIR's latest filing, from -$30.5 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $62.6 million in Q3 2024 and troughed at -$83.0 million in Q4 2023.
• A 5-year average of $11.8 million and a median of $24.8 million in 2022 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation sank 433.98% in 2023, then surged 132.39% in 2024.
• Over 5 years, Share-based Compensation stood at $24.9 million in 2022, then tumbled by 433.98% to -$83.0 million in 2023, then soared by 119.08% to $15.8 million in 2024, then slumped by 292.77% to -$30.5 million in 2025, then soared by 139.58% to $12.1 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $12.1 million, -$30.5 million, and $30.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.